%A Deepjyoti Kumar Das
%A Mohammad Adeel Zafar
%A Sidhanta Nanda
%A Sanpreet Singh
%A Taruna Lamba
%A Hilal Bashir
%A Pargat Singh
%A Sudeep Kumar Maurya
%A Sajid Nadeem
%A Sharvan Sehrawat
%A Vijayender Bhalla
%A Javed Naim Agrewala
%O The copyright of this article belongs to Elsevier. 
%J JOURNAL OF BIOLOGICAL CHEMISTRY
%T Targeting dendritic cells with TLR-2 ligand-coated nanoparticles loaded with Mycobacterium tuberculosis epitope induce antituberculosis immunity
%X ovel vaccination strategies are crucial to efficiently control tuberculosis, as proposed by the World Health Organization under its flagship program ?End TB Strategy.? However, the emergence of drug-resistant strains of Mycobacterium tuberculosis (Mtb), particularly in those coinfected with HIV-AIDS, constitutes a major impediment to achieving this goal. We report here a novel vaccination strategy that involves synthesizing a formulation of an immunodominant peptide derived from the Acr1 protein of Mtb. This nanoformulation in addition displayed on the surface a toll-like receptor-2 ligand to offer to target dendritic cells (DCs). Our results showed an efficient uptake of such a concoction by DCs in a predominantly toll-like receptor-2?dependent pathway. These DCs produced elevated levels of nitric oxide, proinflammatory cytokines interleukin-6, interleukin-12, and tumor necrosis factor-?, and upregulated the surface expression of major histocompatibility complex class II molecules as well as costimulatory molecules such as CD80 and CD86. Animals injected with such a vaccine mounted a significantly higher response of effector and memory Th1 cells and Th17 cells. Furthermore, we noticed a reduction in the bacterial load in the lungs of animals challenged with aerosolized live Mtb. Therefore, our findings indicated that the described vaccine triggered protective anti-Mtb immunity to control the tuberculosis infection.
%N 12
%K Mycobacterium tuberculosis; nanotechnology; peptides; toll-like receptor-2; vaccine.
%V 298
%D 2022
%I Elsevier 
%L open3072